These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8973848)

  • 1. Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma.
    Gibbs SJ; Plowman PN
    Clin Oncol (R Coll Radiol); 1996; 8(6):346-52. PubMed ID: 8973848
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary androgen deprivation therapy in men with prostate cancer.
    Laufman L
    JAMA; 2009 Jan; 301(1):35; author reply 35. PubMed ID: 19126809
    [No Abstract]   [Full Text] [Related]  

  • 3. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 4. Secondary hormonal therapy.
    Smith DC
    Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer: is androgen-deprivation therapy chosen wisely?
    Villanueva MT
    Nat Rev Clin Oncol; 2014 Sep; 11(9):501. PubMed ID: 25073003
    [No Abstract]   [Full Text] [Related]  

  • 6. Measuring the effectiveness of androgen-deprivation therapy for prostate cancer in the medicare population: adequate data are neither the same as nor the enemy of perfect data.
    Trinh QD; Schrag D
    JAMA Intern Med; 2014 Sep; 174(9):1468-9. PubMed ID: 25023522
    [No Abstract]   [Full Text] [Related]  

  • 7. [Revaluation of estrogen therapy on prostate cancer].
    Takezawa Y; Kobayashi M; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():223-7. PubMed ID: 11022718
    [No Abstract]   [Full Text] [Related]  

  • 8. Intermittent androgen ablation as a treatment for prostate cancer.
    Wolff JM
    Front Radiat Ther Oncol; 2002; 36():66-71. PubMed ID: 11842756
    [No Abstract]   [Full Text] [Related]  

  • 9. [Basic and clinical characteristics of flutamide].
    Suzuki K; Nakazato H; Kurokawa K; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():211-5. PubMed ID: 11022716
    [No Abstract]   [Full Text] [Related]  

  • 10. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 11. Intermittent androgen suppression. Too good to be true?
    Abrahamsson PA
    Scand J Urol Nephrol Suppl; 1999; 203():45-9. PubMed ID: 10636570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormonal treatment in prostate cancer].
    Bastide C; Bruyère F; Karsenty G; Guy L; Rozet F
    Prog Urol; 2013 Nov; 23(15):1246-57. PubMed ID: 24183083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure to report financial disclosure information.
    Lu-Yao G; Albertsen P; Shih W; Yao SL
    JAMA; 2009 Jan; 301(1):35-6. PubMed ID: 19126808
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer: Why statins are beneficial.
    Thoma C
    Nat Rev Urol; 2015 Jul; 12(7):360. PubMed ID: 26032545
    [No Abstract]   [Full Text] [Related]  

  • 15. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 16. Progress in Understanding What Is Being Statin(ed) in Prostate Cancer.
    Ramos JD; Yu EY
    JAMA Oncol; 2015 Jul; 1(4):428-30. PubMed ID: 26181247
    [No Abstract]   [Full Text] [Related]  

  • 17. How should we understand the term androgen deprivation therapy?
    Drewa T; Soloway MS
    Eur Urol; 2012 Apr; 61(4):856. PubMed ID: 22266269
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel hormonal therapy for castration-resistant prostate cancer.
    Sternberg CN
    Ann Oncol; 2012 Sep; 23 Suppl 10():x259-63. PubMed ID: 22987973
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal therapies: ADT for prostate cancer: true love or heartbreak?
    Efstathiou JA; Shipley WU; Zietman AL; Smith MR
    Nat Rev Clin Oncol; 2010 Mar; 7(3):130-2. PubMed ID: 20190794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.